Abstract
In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.
| Original language | English |
|---|---|
| Article number | e968028 |
| Journal | Molecular and Cellular Oncology |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2 Jan 2015 |
Bibliographical note
Funding Information:Research leading to these results received funding from the European Research Council Grant Agreements 281738 to E.P. and 294390 to Y.B-N.; the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); the DKFZ-MOST cooperation; and the Israel Science Foundation (ISF) Centers of Excellence (1779/11).
Publisher Copyright:
© 2015, Published with license by Taylor & Francis Group, LLC.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- HCC
- VEGFA
- copy number variation
- genomic amplification
- macrophages
- mouse model
- sorafenib
Fingerprint
Dive into the research topics of 'Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver